ClinicalTrials.gg
CompletedNCT00082446Updated Dec 19, 2014

Combination Study With MVA BN and Dryvax

A Phase 1 interventional study of Live vaccinia virus vaccine and MVA Smallpox Vaccine in Smallpox, sponsored by National Institute of Allergy and Infectious Diseases (NIAID). Completed at 1 site in United States. Open to participants aged 18 Years to 32 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-12-19.

Sponsored by National Institute of Allergy and Infectious Diseases (NIAID) · Phase 1, Interventional, and Prevention

Phase
Phase 1
Study type
Interventional
Enrollment
91
Allocation
Randomized
Ages
18 Years to 32 Years
Sex
All
01

Study summary

The overall goals of this study are to expand the available data on the safety and immunogenicity of MVA-BN in vaccinia-naive adults and to determine the optimum dose of MVA-BN to induce immune responses and attenuate Dryvax take reactions. Participants will include 90 healthy volunteers, ages 18-32 years. Participants will be randomly assigned to 1 of 6 study groups (groups A-F). Participants will be involved in study related procedures for up to 2 years. During this time, volunteers will return periodically for blood draws to check immune responses.

Read the detailed description

The primary goal of this phase I trial is to expand the available data on the safety and immunogenicity of MVA-BN in vaccinia-naïve adults. The secondary goals of this vaccine trial are: to determine the optimum dose of MVA-BN, given twice, to induce an immune response and attenuate Dryvax® take reactions; and to compare the ability of 2 routes of administration of MVA-BN, subcutaneous and intramuscular, to induce an immune response at the highest tested dose. A total of 90 healthy adult volunteers ages 18-32 will participate in this study. The volunteers will be randomly assigned to 1 of 6 groups to be immunized with: MVA-BN (subcutaneously) at 1 of 3 dose levels and Dryvax® (per scarification); placebo (subcutaneously) and Dryvax® (per scarification); MVA-BN (subcutaneously) at the highest dose level and placebo scarification; or MVA-BN (intramuscularly) at the highest dose level and Dryvax® (per scarification). The study will last about 30 months. Each volunteer's participation will last 6 months for all treatment groups. Subjects randomized to treatment groups D and E will have follow-up for 2 years. During this time, volunteers will return periodically for blood draws to check immune responses. Subjects will require visits for dressing changes as needed post-Dryvax vaccination. Variables to be investigated include: adverse events and side effects to the vaccines, and immunogenicity testing including antibody and cellular responses to the vaccines.

02

Conditions studied

  • Smallpox

Browse trials for

Keywords

  • Smallpox, vaccine
03

In context

Smallpox

73 studies on the registry are indexed under Smallpox; 5 are open to participants now.

This study's enrollment of 91 is below the median of 150 across 61 interventional studies indexed under Smallpox.

Browse Smallpox studies →

Lead sponsor

National Institute of Allergy and Infectious Diseases (NIAID) is the lead sponsor of 2,446 studies on the registry; 179 are open to participants now.

Of its 405 completed or terminated interventional studies of FDA-regulated products, 302 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 32 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ages 18-32.
  • Never received smallpox vaccination.
  • Read, signed and dated document.
  • Availability for follow-up for the planned duration of the study two years after first immunization.
  • Acceptable medical history by screening evaluation and limited physical examination.
  • For women, negative serum pregnancy test at screening and negative urine or serum pregnancy test within 24 hours prior to vaccination.
  • If the volunteer is female and of child bearing potential, she agrees to use acceptable , and not become pregnant for at least 56 days after the last vaccination. A woman is considered of child bearing potential unless or surgically sterilized. [Acceptable contraception methods are restricted to effective intrauterine devices (IUDs) or licensed hormonal products with use of method for a minimum of 30 days prior to vaccination.] Women who are not sexually active must agree to use one of the acceptable contraception methods if they are of .
  • Negative ELISA for .
  • \<1.25 times institutional .
  • Negative surface antigen and negative antibody to virus.
  • Negative urine glucose by dipstick or urinalysis.
  • Adequate renal function defined as a serum creatinine less than or equal to 1.4mg/dL for males and less than or equal to 1.2mg/dL for females; urine protein \< 30 mg/dL or none or trace proteinuria (by urinalysis or dipstick); and a calculated creatine clearance greater than or equal to 80 mL/min. based on the following formulas:
  • Males [(140-age in years) X weight in kg]/(72 X serum creatinine)
  • Females 0.85X[(140-age in years) X weight in kg]/(72 X serum creatinine)
  • without clinical significance (e.g., all kinds of atrioventricular or intraventricular conditions or blocks such as complete left or right bundle branch block, AV-node block, or PR prolongation, premature atrial contractions or other atrial arrhythmia, sustained ventricular arrhythmia, or 2 premature ventricular contractions (PVC) in a row, or ST elevation consistent with ischemia)
  • CBC: >11g/dl; White blood cells greater than 2,500 and less than 11,000/cubic mm; greater than or equal to 140,000/cubic mm.

Exclusion criteria

Exclusion Criteria:

  • History of immunodeficiency.
  • Typical vaccinia scar.
  • Known or suspected history of smallpox vaccination.
  • Military service prior to 1989 or after January 2003.
  • Known or suspected impairment of immunologic function including, but not limited to, liver disease; diabetes mellitus; moderate to severe kidney impairment.
  • , including squamous cell skin cancer or basal cell skin cancer at vaccination site or history of skin cancer at the vaccination site.
  • Active disease. Persons with vitiligo or thyroid disease on thyroid replacement are not excluded.
  • History of keloid formation.
  • History of myocardial infarction, angina, congestive heart failure, cardiomyopathy, stroke or , or other heart condition under the care of a doctor.
  • History of an immediate family member (father, mother, brother or sister) who has had onset of ischemic heart disease before age 50 years.
  • Ten percent or greater risk of developing a myocardial infarction or coronary death within the next 10 years using the National Cholesterol Education Program's Risk Assessment Tool for Estimating Your 10-Year Risk of Having a Heart Attack, located at the following URL: http://hin.nhlbi.nih.gov/atpiii/calculator.asp. NOTE: This criterion applies only to volunteers 20 years of age and older.
  • Abnormal troponin I.
  • Use of medication. nasal sprays are permissible. Persons who have used topical steroid can be enrolled after their therapy is completed.
  • Medical or psychiatric condition or occupational responsibilities that preclude volunteer compliance with the protocol.
  • Any history of "illegal" injection drug use.
  • Receipt of inactivated vaccine 14 days prior to vaccination.
  • Receipt of within 30 days of vaccination.
  • Use of experimental agents within 30 days prior to vaccination.
  • Receipt of blood products or immunoglobulin in the 6 months prior to vaccination.
  • Acute febrile illness (greater than or equal to 100.5 degrees F) on the day of vaccination.
  • Pregnant or lactating women.
  • Eczema of any degree or history of eczema.
  • People with atopic dermatitis, Varicella zoster, chronic exfoliative skin disorders/conditions or any acute skin disorders of large magnitude, e.g., laceration requiring sutures, burn greater than 2x2 cm.
  • Household contacts/sexual contacts with, or occupational exposure to (other than minimal contact), any of the following: Pregnant women; Children \<12 months of age; People with or history of eczema; People with atopic dermatitis, Varicella zoster, chronic exfoliative skin disorders/conditions or any acute skin disorders of large magnitude, e.g., laceration requiring sutures, burn greater than 2x2 cm; People with immunodeficiency disease or use of immunosuppressive medications.
  • Any condition that, in the opinion of the investigator, might interfere with study objectives.
  • Known allergies to or any component of MVA or MVA-BN vaccine (e.g., tris(hydroxymethl)-amino methane, sodium chloride, sucrose, dextran, L-Glutamic acid monopotassium, chicken embryo fibroblast proteins, gentamycin).
  • Known allergy to egg or aminoglycoside.
  • Known allergies to any component of the Dryvax® vaccine (e.g. polymyxin B sulfate, dihydrostreptomycin sulfate, chlorotetracycline hydrochloride, neomycin sulfate).
  • Known allergies to any known component of the Dryvax® diluent (i.e. glycerin and phenol).
  • Known allergies to any known components of vaccinia immunoglobulin (VIG), i.e. thimerosal or previous allergic reaction to immunoglobulins.
  • Known allergies to cidofovir or probenecid.
  • Study personnel.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
91 participants (actual)

Study arms

  • Experimental
    E

    Subject will receive an SC dose of MVA 1x10\^8 on day 0 and day 28. On day 112 subjects will receive a dose of placebo by scarification.

    Biological: MVA Smallpox Vaccine · Other: Placebo

  • Active comparator
    D

    Subject will receive a SC dose of placebo on day 0 and day 28. On day 112 subjects will receive a dose of Dryvax® by scarification.

    Biological: Live vaccinia virus vaccine · Other: Placebo

  • Experimental
    C

    Subject will receive a SC dose of MVA 1x10\^8 on day 0 and day 28. On day 112 subjects will receive a dose of Dryvax® by scarification.

    Biological: Live vaccinia virus vaccine · Biological: MVA Smallpox Vaccine

  • Experimental
    B

    Subjects will receive a SC dose of MVA 5x10\^7 on day 0 and day 28. On day 112 subjects will receive a dose of Dryvax® by scarification.

    Biological: Live vaccinia virus vaccine · Biological: MVA Smallpox Vaccine

  • Experimental
    A

    Subjects will receive a SC dose of MVA 2x10\^7 on day 0 and day 28. On day 112 subjects will receive a dose of Dryvax® by scarification.

    Biological: Live vaccinia virus vaccine · Biological: MVA Smallpox Vaccine

  • Experimental
    F

    Subject will receive an IM dose of MVA 1x10\^8 on day 0 and day 28. On day 112 subjects will receive a dose of Dryvax® by scarification.

    Biological: Live vaccinia virus vaccine · Biological: MVA Smallpox Vaccine

Interventions

  • BiologicalLive vaccinia virus vaccine

    Dryvax®: 0.25 mL of vaccine will be administered by the standard route of scarification using a bifurcated needle on day 112 for Groups A, B, C, D and F.

  • Imvamune/MVA-BN 1x10\^8 will be administered intramuscularly to Group F on day 0 and day 28.

  • Imvamune/MVA-BN Groups A, B C and E will be administered subcutaneously: 2x10\^7, 5x10\^7, 1x10\^8, 1x10\^8, respectively, on days 0 and day 28.

  • OtherPlacebo

    Group E will receive sterile saline placebo for injection via scarification on day 112.

  • OtherPlacebo

    Group D will receive sterile saline placebo for injection subcutaneously on day 0 and day 28.

06

What researchers measure

Primary outcomes

  1. Adverse Events and side effects to the vaccines.

    Time frame: Reactogenicity will be evaluated for a 2-week period post-vaccination at each time point and for the duration of study.

Secondary outcomes

  1. Immunogenicity testing of antibody and cellular responses to the vaccines.

    Time frame: Visit days 0, 14, 28, 42, 56, 112, 140, 182, 365, and 730.

07

Study locations

1 site
  • Saint Louis University
    St. Louis, Missouri 63110, United States
08

References and documents

Publications

  • Elizaga ML, Vasan S, Marovich MA, Sato AH, Lawrence DN, Chaitman BR, Frey SE, Keefer MC; MVA Cardiac Safety Working Group. Prospective surveillance for cardiac adverse events in healthy adults receiving modified vaccinia Ankara vaccines: a systematic review. PLoS One. 2013;8(1):e54407. doi: 10.1371/journal.pone.0054407. Epub 2013 Jan 17. PubMed 23349878 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2004, a primary completion of Aug 2007 and a completion of Aug 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 10, 2004
First posted
May 11, 2004
Start
May 2004
Primary completionActual
Aug 2007
CompletionActual
Aug 2007
Last update
Dec 19, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 19, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00082446
Responsible party
Sponsor
First posted
May 11, 2004
Start date
May 2004
Primary completion
Aug 2007
Completion
Aug 2007
Last update
Dec 19, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MVA-BN smallpox vaccine

Start the discussion